Belacabnagene franleucel

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameBelacabnagene franleucel

Drug Alias NameNKX-019

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > γ-retroviral vectorCell and gene therapy > Cell therapy > Donor > Allogeneic +[4]

Mechanisms of ActionAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[15]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto RicoAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNkarta Inc

China Registration ClassN/A

Develop Information

Active CompaniesNkarta Inc

Inactive CompaniesColumbia University

Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[15]

Inactive IndicationsN/A

Other Information

ATC CodeN/A